{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:50:01Z","timestamp":1793605801505,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to evaluate the clinical presentation, diagnostic testing, and outcomes of NL in the rituximab era. Forty biopsy-proven cases of NL, in association with non-Hodgkin lymphoma (NHL), at the Mayo Clinic were retrospectively evaluated. B-cell NHL was associated with 97% of NL cases, of which diffuse large B-cell lymphoma (DLBCL) was the most common (68%). Primary NL, defined as neural involvement present at the time of diagnosis of lymphoma, was noted in 52% cases. Seventy percent of patients presented with sensorimotor weakness and neuropathic pain. Magnetic resonance imaging (MRI) was positive in 100% patients. Overall survival (OS) was significantly better for primary NL and NL associated with indolent lymphomas. Relapses were seen in 60% (24\/40) of patients; 75% involved the peripheral or central nervous system at relapse. The use of rituximab in the frontline setting significantly impacted progression-free survival (PFS). Transplant consolidation was noted to be associated with improved OS. This study adds to the available literature on NL in the rituximab era. The overall outcomes have improved in recent years. In our experience, MRI and positron emission tomography\/computed tomography may be required for accurate assessment of the extent of disease involvement and identification of an optimal biopsy site. The use of rituximab was associated with improvement in PFS, and autologous stem cell transplant was associated with OS.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003666","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T16:33:34Z","timestamp":1614875614000},"page":"1379-1387","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-3653","authenticated-orcid":false,"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, Candiolo, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay M.","family":"Ristow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Lachance","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"2","key":"2021040610451255300_B1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1215\/15228517-5-2-104","article-title":"Neurolymphomatosis","volume":"5","author":"Baehring","year":"2003","journal-title":"Neuro-oncol"},{"issue":"24","key":"2021040610451255300_B2","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","article-title":"Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report","volume":"115","author":"Grisariu","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2021040610451255300_B3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.23464","article-title":"Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma","volume":"46","author":"Flanagan","year":"2012","journal-title":"Muscle Nerve"},{"issue":"2","key":"2021040610451255300_B4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/neuonc\/nop021","article-title":"Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab","volume":"12","author":"Gan","year":"2010","journal-title":"Neuro-oncol"},{"issue":"9","key":"2021040610451255300_B5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/014107689408700915","article-title":"Effects of lymphoma on the peripheral nervous system","volume":"87","author":"Hughes","year":"1994","journal-title":"J R Soc Med"},{"issue":"5","key":"2021040610451255300_B6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/PPO.0b013e31826c5ad5","article-title":"Diagnosis and management of neurolymphomatosis","volume":"18","author":"Baehring","year":"2012","journal-title":"Cancer J"},{"issue":"2","key":"2021040610451255300_B7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/10428194.2017.1352096","article-title":"FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes","volume":"59","author":"Davidson","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2021040610451255300_B8","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1080\/10428194.2017.1312376","article-title":"Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience","volume":"58","author":"Byun","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021040610451255300_B9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/cjn.2017.282","article-title":"Neurolymphomatosis of the brachial plexus and its branches: case series and literature review","volume":"45","author":"Bourque","year":"2018","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"2021040610451255300_B10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3988\/jcn.2016.12.3.274","article-title":"The diagnostic dilemma of neurolymphomatosis","volume":"12","author":"Shree","year":"2016","journal-title":"J Clin Neurol"},{"issue":"9","key":"2021040610451255300_B11","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00415-016-8190-4","article-title":"Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases","volume":"263","author":"Kinoshita","year":"2016","journal-title":"J Neurol"},{"issue":"7","key":"2021040610451255300_B12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00256-019-3145-3","article-title":"B-cell peripheral neurolymphomatosis: MRI and (18)F-FDG PET\/CT imaging characteristics","volume":"48","author":"DeVries","year":"2019","journal-title":"Skelet Radiol"},{"issue":"1","key":"2021040610451255300_B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2021040610451255300_B14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-005-9020-1","article-title":"Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial","volume":"79","author":"Taliansky-Aronov","year":"2006","journal-title":"J Neurooncol"},{"issue":"9","key":"2021040610451255300_B15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MNM.0b013e3283561881","article-title":"Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis","volume":"33","author":"Salm","year":"2012","journal-title":"Nucl Med Commun"},{"issue":"3","key":"2021040610451255300_B16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12185-018-02586-7","article-title":"Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis","volume":"109","author":"Kobayashi","year":"2019","journal-title":"Int J Hematol"},{"issue":"1-2","key":"2021040610451255300_B18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jns.2014.05.058","article-title":"Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes","volume":"343","author":"Kamiya-Matsuoka","year":"2014","journal-title":"J Neurol Sci"},{"issue":"1","key":"2021040610451255300_B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.837","article-title":"Neurolymphomatosis\u2013diagnosis and assessment of treatment response by FDG PET-CT","volume":"26","author":"Lin","year":"2008","journal-title":"Hematol Oncol"},{"issue":"3","key":"2021040610451255300_B20","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2015.6.FOCUS15213","article-title":"Targeted fascicular biopsy of the sciatic nerve and its major branches: rationale and operative technique","volume":"39","author":"Capek","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"18","key":"2021040610451255300_B21","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"issue":"1-2","key":"2021040610451255300_B22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2014.04.030","article-title":"Primary neurolymphomatosis diagnosis and treatment: a retrospective study","volume":"342","author":"Lagarde","year":"2014","journal-title":"J Neurol Sci"},{"issue":"11","key":"2021040610451255300_B23","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/cncr.20263","article-title":"High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis","volume":"100","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"19","key":"2021040610451255300_B24","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021040610451255300_B25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"2021040610451255300_B26","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.bbmt.2020.08.012","article-title":"Outcomes of autologous stem cell transplant consolidation in primary cns lymphoma: a Mayo Clinic experience","volume":"26","author":"Khurana","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2021040610451255300_B27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary cns lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021040610451255300_B28","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2021004700","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1379\/1804663\/advancesadv2020003666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1379\/1804663\/advancesadv2020003666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:55:09Z","timestamp":1671501309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/5\/1379\/475383\/Clinical-manifestations-of-diagnostic-approach-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003666","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2021004700","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}